Kiromic BioPharma, Inc. (KRBP)
USD 0.08
(-2.33%)
USD 0.08
(-2.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -16.3 Million USD | 41.77% |
| 2022 | -32.49 Million USD | -18.8% |
| 2021 | -25.73 Million USD | -30.46% |
| 2020 | -18.99 Million USD | -425.08% |
| 2019 | -3.61 Million USD | -16.64% |
| 2018 | -3.1 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -5.11 Million USD | -54.38% |
| 2024 Q2 | -5.79 Million USD | -17.5% |
| 2023 Q3 | -3.19 Million USD | 22.14% |
| 2023 Q4 | -3.5 Million USD | -9.47% |
| 2023 FY | - USD | 41.77% |
| 2023 Q1 | -4.3 Million USD | 32.45% |
| 2023 Q2 | -4.1 Million USD | 4.44% |
| 2022 Q3 | -7.85 Million USD | 2.17% |
| 2022 Q2 | -8.03 Million USD | -11.85% |
| 2022 FY | - USD | -18.8% |
| 2022 Q1 | -7.18 Million USD | 28.63% |
| 2022 Q4 | -6.36 Million USD | 19.0% |
| 2021 Q2 | -4.86 Million USD | -26.01% |
| 2021 FY | - USD | -30.46% |
| 2021 Q3 | -5.99 Million USD | -23.18% |
| 2021 Q4 | -10.06 Million USD | -67.9% |
| 2021 Q1 | -3.86 Million USD | -10.93% |
| 2020 Q2 | -11.33 Million USD | -523.02% |
| 2020 Q4 | -3.48 Million USD | -47.15% |
| 2020 Q3 | -2.36 Million USD | 79.13% |
| 2020 FY | - USD | -425.08% |
| 2020 Q1 | -1.81 Million USD | 15.23% |
| 2019 Q1 | -365.5 Thousand USD | 0.0% |
| 2019 FY | - USD | -16.64% |
| 2019 Q4 | -2.14 Million USD | -149.86% |
| 2019 Q3 | -858.8 Thousand USD | -246.57% |
| 2019 Q2 | -247.8 Thousand USD | 32.2% |
| 2018 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -3544.42% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 44.753% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 85.707% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -3.427% |
| Better Therapeutics, Inc. | -38.26 Million USD | 57.396% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 57.399% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 8.864% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 51.676% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 51.155% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 84.671% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -1684.53% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 49.815% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 65.088% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -186.804% |
| Molecular Templates, Inc. | 1.43 Million USD | 1239.944% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -17.485% |
| NexImmune, Inc. | -28.16 Million USD | 42.128% |
| Orgenesis Inc. | -60.71 Million USD | 73.153% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 68.22% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -22103.879% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -0.966% |
| Scopus BioPharma Inc. | -11.71 Million USD | -39.17% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 96.981% |
| Statera Biopharma, Inc. | 38.93 Million USD | 141.868% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -136.798% |
| Trevena, Inc. | -35.28 Million USD | 53.805% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -28982.8% |
| Vaccinex, Inc. | -19.74 Million USD | 17.454% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -1456.976% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 65.214% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -124.441% |